Source-grounded facts extracted from PROKIDNEY CORP.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PROKIDNEY CORP. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-28 meeting.
“The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified based on the following results of the voting: For Against Abstain Broker Non Votes 239,091,167 729,165 382,882 –”
PROKIDNEY CORP. shareholders approved Election of three director nominees to serve for three-year terms at the 2026-05-28 meeting.
“Based on the following results of the voting, the Company’s stockholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a three-year term to expire at the Company’s annual meeting of stockholders in 2029 and until their successors are duly elected and qualified: Director Nominee For Withhold Broker Non Votes William F. Doyle 196,164,585 1,459,235 42,579,394 Alan M. Lotvin, M.D. 193,179,768 4,444,052 42,579,394 Brian J.G. Pereira 197,002,580 621,240 42,579,394”
PROKIDNEY CORP. reported the first quarter ended March 31, 2026 results: net income Net loss before noncontrolling interest was $42.6 million.
“ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended March 31, 2026.”
PROKIDNEY CORP. reported financial results for the full year ended December 31, 2025.
“ProKidney Corp. (the "Company") issued a press release to announce its financial results for the year ended December 31, 2025.”
PROKIDNEY CORP.: Adoption of new Bylaws in connection with domestication from Cayman Islands to Delaware.
“ProKidney Delaware adopted a certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”), and the rights of holders of the Common Stock are now governed by such documents and the DGCL.”
PROKIDNEY CORP.: Adoption of new Certificate of Incorporation in connection with domestication from Cayman Islands to Delaware.
“ProKidney Delaware adopted a certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”), and the rights of holders of the Common Stock are now governed by such documents and the DGCL.”
PROKIDNEY CORP.: Adopted new Bylaws in connection with Domestication from Cayman Islands to Delaware.
“The Certificate of Incorporation and Bylaws were effective as of the Domestication Date.”
PROKIDNEY CORP.: Adopted new Certificate of Incorporation in connection with Domestication from Cayman Islands to Delaware.
“The Certificate of Incorporation and Bylaws were effective as of the Domestication Date.”
PROKIDNEY CORP. reported financial results for the first quarter ended March 31, 2024.
“On May 10, 2024, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2024.”
Ulrich Ernst was appointed as Executive Vice President, Technical Operations at PROKIDNEY CORP..
“On March 25, 2024, ProKidney Corp. (the “Company”) announced the appointment of Ulrich Ernst, Ph.D. as the Company’s Executive Vice President, Technical Operations effective as of March 25, 2024.”
PROKIDNEY CORP. reported financial results for the year ended December 31, 2023.
“ProKidney Corp. issued a press release to announce its financial results for the year ended December 31, 2023.”
Deepak Jain resigned as Chief Operating Officer at PROKIDNEY CORP..
“On March 13, 2024 (the “Effective Date”), the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Jain.”
Dr. Bertram departed as ceo at PROKIDNEY CORP..
“On March 13, 2024 (the “Effective Date”), the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Bertram.”
PROKIDNEY CORP. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $100,000,000 (effective 2024-01-19).
“On January 19, 2024, ProKidney Corp. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its Class A ordinary shares, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 through the Sales Agent, acting as agent.”
Bruce Culleton was appointed as Chief Executive Officer at PROKIDNEY CORP..
“In connection with Mr. Culleton’s appointment to serve as the Company’s Chief Executive Officer, on December 3, 2023, Dr. Culleton and ProKidney, LLC, a Delaware limited company and subsidiary of the Company, entered into an employment agreement, effective as of November 15, 2023 (the “Employment Agreement”), pursuant to which Dr. Culleton will serve as Chief Executive Officer of the Company and its subsidiaries and affiliates.”
Deepak Jain was terminated as Chief Operating Officer at PROKIDNEY CORP..
“On November 28, 2023, ProKidney Corp. (“ProKidney” or the “Company”) notified Deepak Jain, Ph.D., Chief Operating Officer of the Company, of the termination of his employment without cause, effective as of the same date, following which Dr. Jain is expected to continue to serve as a consultant to the Company.”
PROKIDNEY CORP. reported financial results for the third quarter ended September 30, 2023.
“On November 14, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended September 30, 2023.”
Bruce Culleton was appointed as Class III Director at PROKIDNEY CORP..
“the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.”
Bruce Culleton was appointed as Chief Executive Officer at PROKIDNEY CORP..
“the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.”
Tim Bertram departed as Director at PROKIDNEY CORP..
“Dr. Bertram will resign from the Board of Directors (the “Board”) of the Company.”
Tim Bertram departed as Chief Executive Officer at PROKIDNEY CORP..
“the board of directors (the “Board”) of ProKidney Corp. (the “Company”) approved the termination, without cause, of Tim Bertram, Ph.D., Chief Executive Officer of the Company, effective November 15, 2023”
PROKIDNEY CORP. reported second quarter ended June 30, 2023 results: net income Net loss before noncontrolling interest was $34.8 million.
“ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments.”
PROKIDNEY CORP. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-29 meeting.
“The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified based on the following results of the voting: For Against Abstain Broker Non Votes 211,255,952 15,231 234”
PROKIDNEY CORP. shareholders approved Election of Directors for a three-year term expiring in 2026 at the 2023-06-29 meeting.
“Based on the following results of the voting, the Company’s shareholders elected the nominees listed below to the Company’s Board of Directors, each to serve for a three-year term to expire at the Company’s annual general meeting of shareholders in 2026 and until their successors are duly elected and qualified: Director Nominee For Against Abstain Broker Non Votes William F. Doyle 204,688,357 86,755 59,329 6,436,976 Alan M. Lotvin, M.D. 204,717,013 86,192 31,236 6,436,976 Brian J. G. Pereira, M.D. 204,658,435 84,994 91,012 6,436,976”
PROKIDNEY CORP. entered into the Agreement with the city of Greensboro, N.C., Guilford County, N.C., and the North Carolina State Economic Investment Committee valued at approximately $25.5 million (effective 2023-06-13).
“On June 13, 2023, ProKidney Corp. (the “Company”) announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company’s future commercial manufacturing needs for REACT ® , its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic chronic kidney disease.”
PROKIDNEY CORP. reported the first quarter ended March 31, 2023 results: net income $36.9 million.
“On May 11, 2023, ProKidney Corp. issued a press release to announce its financial results for the quarter ended March 31, 2023.”
PROKIDNEY CORP. reported financial results for the fiscal year ended December 31, 2022.
“On March 28, 2023, ProKidney Corp. issued a press release to announce its financial results for the fourth quarter and fiscal year ended December 31, 2022.”
PROKIDNEY CORP. reported the fourth quarter ended December 31, 2022 results: net income $24.6 million.
“Net loss before noncontrolling interest was $24.6 million and $13.7 million for the three months ended December 31, 2022, and 2021, respectively.”
PROKIDNEY CORP. reported financial results for third quarter ended September 30, 2022.
“On November 14, 2022, ProKidney Corp. issued a press release to announce the financial results of ProKidney LP and its subsidiaries for the third quarter ended September 30, 2022.”
Jennifer Fox was appointed as member of the board of directors at PROKIDNEY CORP..
“On July 11, 2022, the New ProKidney board of directors appointed Jennifer Fox as a member of the board of directors”
Uma Sinha was appointed as Director at PROKIDNEY CORP..
“On September 24, 2021, Uma Sinha PhD was appointed to the board of directors (the “Board”) of Social Capital Suvretta Holdings Corp. III (the “Company”), effective immediately.”
Marc Semigran was appointed as Director at PROKIDNEY CORP..
“On June 29, 2021, in connection with the IPO, Marc Semigran was appointed to the board of directors of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.